Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic
Open Access
- 1 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (2) , ofx062
Abstract
Background: The introduction of direct-acting antivirals (DAAs) created a major paradigm shift in the treatment of chronic hepatitis C. Currently, there is little “real-world” data regarding hepatitis C virus (HCV) treatment outcomes in the human immunodeficiency virus (HIV)/HCV-coinfected population. Methods: This retrospective cohort study examined HCV treatment outcomes of HIV/HCV-coinfected patients at a large, urban, Ryan White-funded clinic caring for an underserved population. All HIV patients initiating HCV treatment from January 1, 2013 to November 30, 2015 were included in the analysis. The primary end point was sustained virologic response 12 weeks after the end of therapy (SVR12). Results: A total of 172 patients initiated HCV treatment within the study period: 79% were male, 83% were black, 95% were HCV genotype 1, 79% were HCV treatment naive, and 16% had cirrhosis. At baseline, median CD4 was 494 cells/μL (interquartile range, 316–722) and 92% had HIV ribonucleic acid less than 40 copies/mL. The most common DAA initiated was ledipasvir/sofosbuvir (LDV/SOF) (85%), with 92% receiving 12 weeks of treatment. Overall, SVR12 was 93% by intention-to-treat analysis and 98% by per-protocol analysis. The majority of patients on LDV/SOF did not report any adverse effect. One patient in the ribavirin plus SOF group discontinued treatment due to adverse effect. Conclusions: In a cohort of mainly black, male, HIV/HCV-coinfected patients at a large, urban, Ryan White clinic, HCV treatment with DAAs resulted in high SVR12 rates and was well tolerated despite real-world challenges including medication access barriers and drug interaction concerns.Keywords
Funding Information
- Gilead Sciences
This publication has 20 references indexed in Scilit:
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1New England Journal of Medicine, 2015
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1New England Journal of Medicine, 2015
- P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous populationJournal of Hepatology, 2015
- Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infectionJAMA, 2015
- Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1JAMA, 2015
- Experience of acute hepatitis C and HIV co‐infection in an inner city clinic in the UKJournal of the International AIDS Society, 2014
- Hepatitis C in African AmericansAmerican Journal of Gastroenterology, 2014
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV CoinfectionJAMA, 2014
- Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCVJAMA, 2012
- Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease ProgressionClinical Infectious Diseases, 2009